RCT ICU patients in Russia, showing significantly increased lymphocyte counts with treatment. Mortality was lower but without statistical significance. Authors used cholecalciferol. Calcifediol or calcitriol, which avoids several
days delay in conversion, may be more appropriate and successful, especially
with this very late stage usage.
40% of patients were on mechanical ventilation at baseline in the treatment group, compared to 30% in the placebo group.
Authors state that there has been 6 RCTs for COVID-19 and vitamin D, however there was at least 23 at the time of publication: [c19early.org]
Although the 27% lower mortality is not statistically significant, it is consistent with the significant 37% lower mortality [28‑44%]
from meta analysis of the 59 mortality results to date
Bychinin et al., 3 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Russia, peer-reviewed, 7 authors, average treatment delay 9.0 days, dosage 60,000IU day 1, 5,000IU days 2-7, 8, 5,000IU days 9-14, 15, 5,000IU days 16-21, 22, 5,000IU days 23-28, trial NCT05092698 (history)